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Low-dose persistent organic pollutants (POPs), especially
organochlorine pesticides (OCPs) and polychlorinated
biphenyls (PCBs), have emerged as a new risk factor for
type 2 diabetes. We evaluated whether chronic exposure
to low-dose POPs affects insulin secretory function of
b-cells in humans and in vitro cells. Serum concentrations
of OCPs and PCBs were measured in 200 adults without
diabetes. Mathematical model–based insulin secretion in-
dices were estimated by using a 2-h seven-sample oral
glucose tolerance test. Insulin secretion by INS-1E b-cells
was measured after 48 h of treatment with three OCPs
or one PCB mixture. Static second-phase insulin secretion
significantly decreased with increasing serum concentra-
tions of OCPs. Adjusted means were 63.2, 39.3, 44.1, 39.3,
39.7, and 22.3 across six categories of a summary
measure of OCPs (Ptrend = 0.02). Dynamic ﬁrst-phase in-
sulin secretion remarkably decreased with increasing
concentrations of OCPs among only insulin-sensitive
individuals (Ptrend = 0.02); the insulin levels among indi-
viduals with high OCPs were ∼30% of those with low
OCPs. Compared with OCPs, PCBs showed weaker as-
sociations. The decreased insulin secretion by INS-1E
b-cells was observed for even 1 pmol/L OCP. The data
from human and in vitro cell experiments suggest that
chronic exposure to low-dose POPs, especially OCPs,
can induce pancreatic b-cell dysfunction.
Chronic exposure to low-dose chlorinated persistent organic
pollutants (POPs), especially organochlorine pesticides (OCPs)
and polychlorinated biphenyls (PCBs), has been linked to the
risk of type 2 diabetes (T2D) (1). POPs include several hun-
dred highly lipophilic chemicals that bioaccumulate mainly
in adipose tissue and are resistant to biodegradation (1).
Although most chlorinated POPs were banned several de-
cades ago in many countries, the modern general population
is exposed to these chemicals through POP-contaminated
foods, such as fatty animal foods, seafood, dairy products,
and breast milk (1). Besides, these chemicals stored in ad-
ipose tissue are an important internal exposure source (1).
The release of these chemicals from adipose tissue is mech-
anistically linked to adiposity, a traditional risk factor of
T2D (1,2).
Both insulin resistance (IR) and b-cell dysfunction are
important for the development of T2D, but many people
exhibit predominantly either IR or b-cell dysfunction (3).
Moreover, the role of obesity, the most important known
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risk factor of T2D, seems to differ depending on the types
of T2D preceded predominantly by IR versus b-cell dysfunc-
tion (4). Although overweight and obesity are the most
important risk factors of IR-dominant T2D, the role of ad-
iposity is weak in T2D preceded predominantly by b-cell
dysfunction (4). At present, genetic predisposition is con-
sidered a key determinant of b-cell function (5).
Although epidemiological and experimental studies have
revealed the relationship of POPs with IR (6,7), some hu-
man studies have suggested that direct toxicity of POPs to
b-cells (rather than to decreased peripheral insulin sensitiv-
ity) may be a more plausible mechanism linking POPs and
T2D (8–10). For example, serum concentrations of POPs
were related to the markers of b-cell dysfunction (e.g.,
HOMA-b and 2-h insulin after oral glucose tolerance test
[OGTT]), not IR markers among Greenland Inuit without
diabetes (9). In addition, serum concentrations of PCBs
were related to low levels of fasting insulin or HOMA-b,
not IR, among children (8,10). On the other hand, in one
study that used an intravenous glucose tolerance test, p,p9-
dichlorodiphenyltrichloroethane (DDT), not other POPs,
was associated with both HOMA-IR and ﬁrst-phase insulin
secretion after adjustment for peripheral insulin sensitivity
(11). Because decreased insulin secretion as a result of pan-
creatic b-cell dysfunction is crucial for the development of
overt T2D (12), careful evaluation of the association be-
tween POPs and insulin secretion is important to under-
stand the role of POPs in the pathogenesis of T2D.
Although hyperglycemic-euglycemic insulin clamp tech-
niques are widely considered gold standard methods for
assessing insulin secretion and IR in vivo (13), these ap-
proaches are difﬁcult to apply practically to epidemiological
studies. Several surrogate measures are derived from OGTTs
or fasting insulin and glucose, but all these methods have
limitations, and correlations among the indices are modest
(14).
We assessed mathematical model–based insulin secre-
tion (dynamic ﬁrst- and static second-phase of b-cell func-
tion) and insulin sensitivity among participants without
diabetes by using a 2-h seven-sample OGTT, a reduced
version of a 5-h 11-sample full oral minimal model assess-
ment that was validated against clamp methods (15,16),
and evaluated the relationship with serum concentra-
tions of OCPs or PCBs. In addition, we determined whether
the ﬁndings in humans were reproduced in in vitro cell
experiments.
RESEARCH DESIGN AND METHODS
Study Participants
Two hundred patients were recruited at the Routine Health
Checkup Center of Kyungpook National University Hospi-
tal, Daegu, Korea, from October 2013 to December 2015.
Among patients age .30 years, those with at least one of
the following criteria were excluded: 1) any history of
diabetes, myocardial infarction, stroke, or heart failure; 2)
diagnosis of cancer within previous 5 years; 3) current
participation in any clinical drug trial; or 4) pregnancy.
We obtained written informed consent from each partici-
pant. The study’s protocol was reviewed and approved by
the Institutional Review Board of Kyungpook National Uni-
versity Hospital (IRB No. KNUH 2013-12-016).
Measurements
Detailed information on general characteristics and health-
related behaviors is provided in the Supplementary Data.
Before venous blood sampling, all the participants fasted
overnight for at least 8 h. Approximately 5 mL of serum
was drawn from each participant, and the samples were
kept in a freezer at 270°C until analysis. Total cholesterol
and triglyceride levels were measured by an enzymatic
method by using an ADVIA 1800 autoanalyzer (Siemens
Medical Solutions, Malvern, PA). Glucose was measured by
a colorimetric method on the same analyzer. Insulin and
C-peptide were quantiﬁed by a radioimmunoassay
method (SR-300; STRATEC, Birkenfeld, Germany). Intra-
and interassay coefﬁcients of variation were 0.5 and 0.8
for glucose, 1.8 and 6.3 for insulin, and 2.7 and 4.0 for
C-peptide, respectively.
Two-Hour Seven-Sample OGTT
For the minimal model assessment of pancreatic b-cell
responsivity, we used a 2-h OGTT protocol that consisted of
seven venous blood samplings at 0, 10, 20, 30, 60, 90, and
120 min after ingestion of 75 g of glucose at time 0 (15).
Plasma glucose, insulin, and C-peptide levels were measured
for each sample.
Indices of Insulin Sensitivity and Insulin Secretion
of Pancreatic b-Cells
Indices of insulin sensitivity and insulin secretion were
obtained from seven samples of glucose, insulin, and
C-peptide concentrations measured during the OGTT
protocol by using the minimal model (17–19) and were
calculated by means of SAAM II (Simulation Analysis and
Modeling) version 2.1 software (https://tegvirginia.com/
solutions/saam-ii) and the individual estimates from the
2-h seven-sample OGTT. The insulin sensitivity index is
the ability of insulin to stimulate glucose disposal and in-
hibit glucose production (20). Insulin secretion indices con-
sist of two components: dynamic phase secretion (Fd) and
static phase secretion (Fs) (15); Fd is the amount of dy-
namic ﬁrst-phase secretion of insulin per unit increase of
glucose, which is used to assess the appropriateness of in-
sulin secretion in response to a change in glucose; Fs is
over-basal average static second-phase secretion of insulin
per unit over-basal average glucose, which is used to assess
the appropriateness of insulin secretion for a given glucose
level (20). The disposition index (DI) is a product of the
insulin sensitivity index (SI) and b-cell insulin secretion.
Thus, dynamic phase DI (DId) = Fd 3 SI, and static phase
DI (DIs) = Fs 3 SI (20).
In addition, we calculated conventional estimators HOMA-
IR and HOMA-b to assess insulin sensitivity and insulin
release in most epidemiological studies. The equations are
as follows: HOMA-IR = (fasting insulin [mIU/mL] 3 fasting
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plasma glucose [mmol/L])/22.5 and HOMA-b = (20 3
fasting plasma insulin [mIU/mL])/(fasting plasma glucose
[mmol/L] 2 3.5) (21).
Measurement of POPs in Serum
Serum concentrations of POPs, including PCBs and OCPs,
were analyzed in the laboratory of Hanyang University
(Ansan, Korea) by using high-resolution gas chromatogra-
phy with high-resolution mass spectrometry (AutoSpec
Premier; Waters, Milford, MA). POP concentrations in
serum were reported as the wet weight in picograms per
milliliter. The limit of detection (LOD) was deﬁned as the
concentration that generated a signal equal to three times
the baseline noise. In the analysis, POP concentrations
below the LOD were replaced with LOD / 3. Thirty-seven
POPs (18 OCPs, 19 PCBs) were quantiﬁed, but we evaluated
4 OCPs and 6 PCBs for which at least 70% of the participants
had concentrations above the LOD: p,p9-DDT; p,p9-dichlor-
odiphenyldichloroethylene (DDE); b-hexachlorocyclohexane
(HCH); trans-nonachlor; PCB118; PCB138; PCB153;
PCB170; PCB180; and PCB187. We tried both wet-weight
concentrations with lipid adjustment (including serum
concentrations of triglycerides and total cholesterol as
covariates) and lipid-standardized concentrations (by divid-
ing wet-weight concentrations by total lipids [total lipids
(mg/dL) = 2.27 3 total cholesterol + triglycerides + 62.3])
(22). Because they showed similar associations, we present
the results of wet-weight concentrations.
Supplementary Table 1 shows the detection rate and
distribution of POP concentrations. For a direct comparison
of results with the in vitro cell study, we present concentra-
tions of POPs in molar units (nmol/L) in cases of b-HCH,
p,p9-DDT, trans-nonachlor, and the mixture of PCBs.
In Vitro Experiments
Insulin secretion and insulin content were analyzed to assess
the chronic effects of three low-dose OCPs (p,p9-DDT;
b-HCH; and trans-nonachlor) and Aroclor 1254 (PCB
mixture) on INS-1E b-cells. For insulin assays, 3.0 3 105
INS-1E cells per well were seeded in 24-well plates with
complete RPMI medium and grown for 48 h. The cells were
preincubated in the RPMI medium containing 0.5% of FBS
for 1 h followed by incubation with various concentrations
of each compound (10212–1026 mol/L) for 48 h. The OCPs
and PCB mixture were dissolved and stored in absolute
methanol. The ﬁnal concentration of methanol in the media
was 0.1% volume for volume, including the control. Measure-
ment of glucose-stimulated insulin secretion was performed
as previously described (23,24) with some modiﬁcations.
Detailed information on in vitro experiments is provided
in the Supplementary Data.
Statistical Analysis
Serum concentrations of individual POPs were catego-
rized into quartiles, and the last quartile was further
categorized with the cutoff points of 90th and 95th
percentile levels because the range of the last quartile
was too wide, and insulin secretion clearly decreased
with increasing concentrations of POPs, even within the
4th quartile (Q4). In addition, we determined the summary
measures of OCPs and PCBs by summing the ranks of the
individual congeners of four OCPs (p,p9-DDT; p,p9-DDE;
b-HCH; and trans-nonachlor) and six PCBs (PCB118,
PCB138, PCB153, PCB170, PCB180, and PCB187), respec-
tively. The summary measures were also categorized into
groups by cutoff points at the 25th, 50th, 75th, 90th, and
95th percentile levels. Distributions of each compound
according to the categories of the summary measures of
OCPs and PCBs are presented in Supplementary Table 2.
In fact, human studies on POPs should be interpreted
by primarily focusing on the summary measures of POPs
rather than on individual compounds because the serum
concentrations of individual compounds highly correlate in
the general population (correlation coefﬁcients among four
OCPs and six PCBs in this study: 0.35–0.87 and 0.76–0.98,
respectively). In this situation, interpretation that focuses
on individual compounds may be misleading. Among sev-
eral methods for estimation of the summary measures
of POPs (1), we used the summary measure that sums the
rank orders of individual compounds belonging to each sub-
class; this approach enables equal contributions from all
constituent compounds. Absolute concentration–based
summary measures seem to be intuitively reasonable, but
their results are similar to those of a couple of individual
compounds with much higher absolute concentrations com-
pared with the other compounds. The advantage of a rank-
based summary measure of POPs over other methods is
discussed in detail elsewhere (1).
Insulin secretion and sensitivity indices were log-
transformed, controlling for the skewed distribution. Ad-
justed geometric means of insulin secretion and sensitivity
indices according to POP concentrations were estimated by
using the generalized linear model. The covariates were
age (continuous, years), sex (male/female), BMI (continu-
ous, kg/m2), cigarette smoking (continuous, pack-years),
alcohol consumption (continuous, g/week), physical activity
(continuous, MET-min/week), total cholesterol (continuous,
mg/dL), and triglycerides (continuous, mg/dL). When the in-
dices of insulin secretion were an outcome variable, insulin
sensitivity was also considered as a covariate or an effect
modiﬁer because insulin secretion from pancreatic b-cells is
directly affected by insulin sensitivity. Correlation coefﬁ-
cients of covariates with insulin sensitivity/insulin secretion
indices are provided in Supplementary Table 3. All data were
analyzed with SAS 9.4 software (SAS Institute, Cary, NC).
RESULTS
Human Study
Table 1 shows general characteristics of the study par-
ticipants. Among the 200 participants, 36% were male.
The mean age was 55.1 years, and the mean BMI was
24.6 kg/m2. Current smokers and current drinkers con-
stituted 11.5% and 49.5% of the cohort, respectively.
Correlation coefﬁcients of BMI and health behaviors with
the summary measures of OCPs and PCBs are shown in
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Supplementary Table 4. BMI showed a weak positive corre-
lation with the summary measure of OCPs but not with the
summary measure of PCBs.
Markers of insulin sensitivity and secretion estimated on
the basis of 2-h seven-sample OGTT were only weakly
associated with HOMA-IR and HOMA-b, which were
estimated on the basis of fasting glucose and insulin (Sup-
plementary Table 5). Correlation coefﬁcients between static
and dynamic insulin secretion estimated by means of 2-h
seven-sample OGTT with HOMA-b were 0.26 and 0.30,
respectively.
Table 2 shows the association between summary mea-
sures of OCPs or PCBs and markers of insulin secretion and
sensitivity indices among all the participants. Results on
individual compounds belonging to OCPs and PCBs are
presented in Supplementary Tables 6 and 7. In crude mod-
els, insulin sensitivity decreased as the summary measure of
OCPs or PCBs increased (Ptrend , 0.01 for OCPs and 0.01
for PCBs). Among the markers of insulin secretion, Fs
significantly decreased as the summary measure of OCPs
or PCBs increased (Ptrend , 0.01 for OCPs and 0.03 for
PCBs), whereas Fd was not statistically signiﬁcant de-
spite a decreasing tendency with increasing dose of OCPs
or PCBs.
After adjustment for age, sex, BMI, cigarette smoking,
alcohol consumption, physical activity, total cholesterol,
and triglycerides (model 2), only the inverse relation
between OCPs and Fs remained signiﬁcant; adjusted geo-
metric means of Fs were 63.4, 38.4, 44.2, 39.4, 40.1, and
22.7 across six categories of summary measures of
OCPs (,25%, 25 to ,50%, 50 to ,75%, 75 to ,90%,
90 to,95%,$95%; Ptrend = 0.03). When insulin sensitivity
was further adjusted (model 3), the relation remained un-
changed. OCPs also showed a decreasing tendency with
static DI, with a marginal statistical signiﬁcance (Ptrend =
0.06). On the other hand, when HOMA-IR and HOMA-b
were used as markers of insulin sensitivity and insulin se-
cretion, the summary measure of PCBs was inversely asso-
ciated with HOMA-b (Ptrend = 0.02 in model 3), whereas
OCPs were not related to either.
Evaluation of the association of OCPs or PCBs with
glucose during fasting and at 2 h showed that glucose levels
at 2 h gradually increased with increasing serum concen-
trations of OCPs and PCBs, whereas the increase in fasting
glucose was prominent in the highest 5th percentile group
of OCPs or PCBs (Supplementary Table 8). We repeated all
these analyses after excluding those with concentrations
below the LOD as a sensitivity analysis, and the results
were very similar to those among all participants (Sup-
plementary Table 9).
We next assessed the associations of POPs with insulin
secretion by the levels of IR (Fig. 1) and found a statistically
signiﬁcant interaction between the summary measure of
OCPs and HOMA-IR on Fd (Pinteraction = 0.01). Among par-
ticipants with HOMA-IR ,1.95 (median value; relatively
insulin-sensitive individuals), a strong inverse association
was observed between OCPs and Fd (Ptrend = 0.02); the
adjusted mean of insulin secretion among participants
in Q4 of OCPs was ,30% of that in the Q1 of OCPs. In
contrast, no association was found between OCPs and
Fd among participants with HOMA-IR $1.95 (relatively
insulin-resistant individuals). Similarly, the Fs also showed
a tendency for a stronger inverse association with OCPs
among relatively insulin-sensitive individuals compared
with relatively insulin-resistant individuals, although the P
value for the interaction was not statistically signiﬁcant
(Fig. 1).
Results for PCBs were generally weaker than those for
OCPs (Fig. 2). PCBs showed a clearer pattern of interaction
with HOMA-b (Pinteraction = 0.09) than with markers of in-
sulin secretion on the basis of the 2-h seven-sample OGTT
(Pinteraction = 0.69 for Fs and 0.12 for Fd). As in the OCP
ﬁndings, the decreasing trend of insulin secretion was
clearer among relatively insulin-sensitive individuals than
among relatively insulin-resistant individuals.
When we tried tertiles of HOMA-IR in sensitivity
analyses and participants were restricted to the relatively
insulin-sensitive individuals, the patterns became more
prominent (Supplementary Figs. 1 and 2). Of note, PCBs
also showed a marginally signiﬁcant interaction with
Fd (Pinteraction = 0.07). On the other hand, when the marker
of insulin sensitivity, which was estimated by the 2-h
seven-sample OGTT, was used instead of HOMA-IR, the
interactions were not observed. The results of individual
compounds belonging to OCPs and PCBs are presented
in Supplementary Tables 10 and 11.
When we evaluated the associations of obesity indices
(BMI, waist circumference, and percent body fat) with
insulin secretion and sensitivity indices without consid-
eration of POPs, only insulin sensitivity clearly decreased
with increasing obesity (Table 3). Neither Fs nor Fd was
associated with obesity indices.
Table 1—General characteristics of study participants
Characteristic Value
Age (years) 55.1 6 12.1 (30–71)
Sex
Male 72 (36.0)
Female 128 (64.0)
BMI (kg/m2) 24.6 6 3.3 (17.0–37.4)
,25 117 (58.5)
$25 to ,30 71 (35.5)
$30 12 (6.0)
Cigarette smoking
(pack-years) 6.7 6 13.6 (0–60)
Alcohol consumption
(g/week) 79.0 6 223.9 (0–2,580)
Physical activity
(MET-min/week) 2,749.2 6 3,796.3 (0–24,318.0)
Total cholesterol (mg/mL) 185.7 6 32.4 (114.0–313.0)
Triglycerides (mg/mL) 128.2 6 78.4 (34.0–536.0)
Data are mean 6 SD (minimum–maximum) or n (%).
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In Vitro Experiments
The decreased insulin secretion after stimulation by glucose
was observed for 10212 mol/L p,p9-DDT and b-HCH (Fig.
3A). At 1029 mol/L, insulin secretion levels were signiﬁ-
cantly decreased for all OCPs and Aroclor 1254. However,
in the range of doses differing by;106-fold (10212–1026
mol/L), no linear dose-response relations were observed,
but nonmonotonic dose-response relations with some
ﬂuctuations were. Little or no effect of OCPs or Aroclor
1254 on the basal insulin secretion level was found
(Supplementary Fig. 3).
Insulin content also signiﬁcantly decreased in cells
treated with p,p9-DDT (10212–1026 mol/L, except 10211
mol/L); trans-nonachlor (10210–1026 mol/L, except 1028
mol/L); and Aroclor 1254 (1027–1026 mol/L) (Fig. 3B). In
contrast, the insulin content in b-HCH–treated cells
signiﬁcantly increased at low concentrations (10212–10211
mol/L). A very low concentration (10211 mol/L) of Aroclor
1254 also yielded an increased concentration of intracellular
insulin content. Again, no linear dose-response relations
were found.
The ratio of insulin secretion/insulin content revealed
different mechanisms of action among different chemical
compounds (Fig. 3C). For example, p,p9-DDT showed the
most consistent decrease pattern for insulin secretion and
intracellular insulin content in INS-1E cells. Both b-HCH
and Aroclor 1254 seemed to primarily decrease insulin se-
cretion. In the case of trans-nonachlor, decreased insulin
synthesis seemed to be more pronounced than decreased
insulin secretion.
DISCUSSION
On the basis of human and in vitro studies, we demonstrate
that chronic exposure to low-dose POPs can induce pan-
creatic b-cell dysfunction. POPs were found to be more
strongly related to markers of insulin secretion than to
IR. Between two common subclasses of POPs, OCPs showed
more consistent results compared with PCBs. For example,
Fs among participants in the highest 5th percentile of the
summary measure of OCPs was only one-third of those in
the lowest 25th percentile. In contrast to POPs, obesity
indices, such as BMI, waist circumference, and percent
body fat, were found to be strongly associated only with
IR but not with indices of insulin secretion.
Of note, the associations of POPs withFd were different
depending on the levels of HOMA-IR. The inverse asso-
ciations between these chemicals with Fd were observed
among insulin-sensitive individuals and not in insulin-
resistant individuals. Among insulin-sensitive individuals,
the insulin levels among those in Q4 of OCPs were only
20–30% of those in Q1 of these chemicals. However, these
strong inverse associations completely disappeared as
HOMA-IR increased. The Fs also showed a similar interac-
tion, but the pattern was weaker than that of Fd. All these
interactions were more pronounced when the analysis was
restricted to more insulin-sensitive individuals.
Figure 1—Associations between insulin secretion indicators (A–E) and concentrations of OCPs stratiﬁed by the level of HOMA-IR.∑OCPs: rank
sum of four OCPs (p,p9-DDT; p,p9-DDE; b-HCH; and trans-nonachlor) adjusted for age, sex, BMI, cigarette smoking, alcohol consumption,
physical activity, total cholesterol, triglycerides, and insulin sensitivity. For the analyses in which the static and dynamic DIs are dependent
variables, insulin sensitivity was excluded from the preceding covariates.●, insulin-sensitive group (HOMA-IR<1.95);□, insulin-resistant group
(HOMA-IR $1.95).
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As people become insulin resistant, a compensatory
oversecretion of insulin occurs as long as the pancreatic
b-cells work. Therefore, no association of POPs with
Fd among insulin-resistant individuals suggests that the
inverse association between POPs and insulin secretion is
masked by the hyperactivation of pancreatic b-cells. This
notion indicates that the detrimental effect of chronic ex-
posure to low-dose POPs on pancreatic b-cells may be the
result of reversible functional impairment (which can be
overcome by the compensatory mechanism to activate pan-
creatic b-cells) as opposed to the direct cellular toxicity
resulting from high-dose chemical exposure that leads to
irreversible cell damage.
The possibility of the reversible functional impairment
of pancreatic b-cells is also supported by the ﬁndings from
in vitro experiments. In this study, the treatment of INS-1E
b-cells with 1 pmol/L p,p9-DDT for 48 h decreased the in-
sulin secretion and intracellular insulin content, but no
further decrease was observed with an increase in the
dose of p,p9-DDT to 1 mmol/L. Other compounds also
demonstrated nonlinearity. Because direct cellular toxicity
commonly shows a linear dose-response relation, it may not
be a plausible mechanism underlying the decreased insulin
secretion or intracellular insulin content resulting from
POPs.
Low levels of POPs may indirectly affect the function of
INS-1E b-cells, and this pathway can be compensated
by an increased dose of POPs through certain biological
mechanisms. The possibility of nonlinearity was sug-
gested in our review article summarizing various epide-
miological and experimental studies of POPs and T2D
(1). Of note, mitochondrial dysfunction, a possible molecu-
lar mechanism linking POPs and T2D (1,7,25), can be com-
pensated by the induction of cellular protective mechanisms
by slightly increased doses of chemicals; this phenomenon
is called hormesis (26).
In addition, the current in vitro experiments suggest
that different chemical compounds have different molecular
mechanisms of action. For example, p,p9-DDT showed the
most consistent pattern for decreased insulin secretion and
a decrease in intracellular insulin content. Both b-HCH and
Aroclor 1254 seemed to primarily decrease insulin secre-
tion. In the case of trans-nonachlor, decreased insulin syn-
thesis seemed to be more important than decreased insulin
secretion. Mechanistically, decreased insulin content in the
in vitro experiments may be relevant to the decreased Fs,
whereas the decreased insulin secretion may be relevant to
Fd. Nonetheless, because humans are exposed to all these
chemical mixtures, both Fd and Fs can be affected by POP
mixtures.
The POP-related decrease in insulin secretion may
explain the risk of T2D in Asian and elderly people.
Compared with people of European descent, Asians with
T2D are characterized by early b-cell dysfunction, which
develops at a lower BMI (27). At present, genetic predis-
position and a greater tendency for visceral adiposity at any
Figure 2—Associations between insulin secretion indicators (A–E) and concentrations of PCBs stratiﬁed by the level of HOMA-IR. ∑PCBs:
rank sum of six PCBs (PCB118, PCB138, PCB153, PCB170, PCB180, and PCB187) adjusted for age, sex, BMI, cigarette smoking, alcohol
consumption, physical activity, total cholesterol, triglycerides, and insulin sensitivity. For the analyses in which the static and dynamic DIs are
dependent variables, insulin sensitivity was excluded from the preceding covariates. ●, insulin-sensitive group (HOMA-IR <1.95); □, insulin-
resistant group (HOMA-IR $1.95).
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given BMI are suspected to contribute to ethnic disparities
in T2D (27). However, the levels of many chemicals belong-
ing to the POP class in both humans and the environment
are higher in many Asian countries than in Western Europe
or North America because emission sources of many POPs
in the past several decades have shifted from industrialized
countries of the northern hemisphere to less-developed
countries in tropical and subtropical regions (28). Thus,
chronic exposure to POPs and other chemicals may be the
key reason why b-cell dysfunction–dominant T2D is more
common among Asians than among Caucasians. Similarly,
the role of POPs in the development of T2D may become
more important with aging, given that the body’s burden of
POPs is higher in elderly people than in younger people
because lipophilic chemicals like POPs tend to accumulate
with age (29). This observation may explain why insulin
secretory defects are more prevalent in T2D for older (30)
than for middle-aged adults.
A couple of epidemiological studies suggested that
traditional risk factors of T2D, including obesity, have
varying relations with incident T2D, depending on preceding
degrees of IR or pancreatic b-cell dysfunction before diag-
nosis (4,31). In particular, among elderly people, greater
adiposity and signiﬁcant weight gain have been linked to
even lower rates of incident T2D preceded predominantly
by b-cell dysfunction (4,31). These puzzling results also can
be explained by POPs because adipose tissue is a major
storage site for POPs and can play a primarily protective
role against the effects of POPs on critical organs. For
example, when two elders are exposed to the same amounts
of POPs from the environment, the one with less adi-
posity has an increased chance of POPs reaching pancre-
atic b-cells (2).
Although HOMA-b has been widely used in epidemio-
logical studies to estimate insulin secretion because of its
convenience, it may have a limited value for the evaluation
Figure 3—Effects of OCPs or Aroclor 1254 (PCB mixture) on glucose-stimulated insulin secretion in INS-1E b-cells. Each chemical was
incubated with INS-1E cells at concentrations from 10212 to 1026 mol/L for 48 h. Streptozotocin (STZ) at 2.5 3 1024 mol/L served as a positive
control for b-cell damage. At the end of the incubation period, media were collected to measure secreted insulin (A), and the cells were subjected
to extraction to measure cellular insulin content (B). Ratios of insulin secretion to insulin content are also presented (C). Data are mean 6 SE of
six independent samples. *P < 0.05, **P < 0.001 vs. control.
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of the effects of POPs and other chemicals on pancreatic
b-cell function. When we compared the results of insulin
secretion estimated by 2-h seven-sample OGTT with those
of HOMA-b, the results differed depending on how in-
sulin secretion was measured. Different associations would
be expected because correlation coefﬁcients among these
markers were not .0.3. In addition, the clearly contrasting
associations between POPs andFd by insulin-resistant levels
suggest that the accurate analysis of different phases of in-
sulin secretion is important. Furthermore, the interaction
between POPs and insulin-resistant levels on Fd was ob-
served when HOMA-IR, not the marker of insulin sensitiv-
ity estimated by 2-h seven-sample OGTT, was used as a
marker of insulin sensitivity. This ﬁnding may be related to
the fact that OGTT provides useful information about glucose
tolerance but not insulin sensitivity/IR per se (32,33). All these
ﬁndings suggest that how insulin secretion and insulin sen-
sitivity are measured in human studies is important.
The study has several limitations. First, it was cross-
sectional, which does not allow for determination of a
temporal relation. Nonetheless, that pancreatic b-cell
function affects serum concentrations of OCPs or PCBs is
unlikely. In addition, the supporting evidence from our
in vitro experiments suggests that the associations observed
in this study may be causal. In a future study, we can
evaluate whether POPs affect the course of b-cell function
over time. Second, we assessed insulin secretion and insulin
sensitivity by using a reduced version of the oral minimal
model rather than gold standard techniques, such as the
hyperglycemic-euglycemic clamp, for practical reasons.
However, the use of OGTT can be preferable for physiolog-
ical signiﬁcance, not for simplicity (14).
In conclusion, this study provides important ﬁndings
that mechanistically support the recent evidence linking
POPs and T2D (1). Chronic exposure to low doses of POPs
may increase the risk of T2D by primarily affecting pancre-
atic b-cell function rather than IR. Because the impairment
of insulin secretion (rather than impairment of insulin ac-
tion) is a critical determinant of T2D (34), the inﬂuence of
POPs on pancreatic b-cell function should be urgently eval-
uated in a prospective study.
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